Xerion Pharmaceutical GmbH – Trademark Portfolio

Entity Type: 11

Xerion Pharmaceutical GmbH holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. The owner is based in 82152 Planegg.

Fraunhoferstrasse 9

82152 Planegg , DE

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

X-PLORE
X-PLORE
Cancelled 1999
XERION
XERION
Cancelled 1999

Trademark Classifications

Xerion Pharmaceutical GmbH's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

7
Machinery (1 filing)

Machines and machine tools; motors and engines; machine coupling and transmission components

Frequently Asked Questions

How many trademarks does Xerion Pharmaceutical GmbH have?

Xerion Pharmaceutical GmbH has 2 U.S. trademarks filed with the USPTO.

What trademark classes does Xerion Pharmaceutical GmbH file in?

Xerion Pharmaceutical GmbH files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 7 (Machinery). Class 42 covers scientific and technological services; industrial analysis and research services.

What is Xerion Pharmaceutical GmbH's trademark registration success rate?

Xerion Pharmaceutical GmbH has a 0% trademark registration rate, with 0 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.